Darbepoetin Alfa

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Myelodysplastic Syndrome (MDS)

Conditions

Myelodysplastic Syndrome (MDS)

Trial Timeline

Jun 12, 2014 → Mar 20, 2017

NCT ID

NCT02175277

About Darbepoetin Alfa

Darbepoetin Alfa is a phase 3 stage product being developed by Amgen for Myelodysplastic Syndrome (MDS). The current trial status is completed. This product is registered under clinical trial identifier NCT02175277. Target conditions include Myelodysplastic Syndrome (MDS).

What happened to similar drugs?

7 of 18 similar drugs in Myelodysplastic Syndrome (MDS) were approved

Approved (7) Terminated (7) Active (6)

✅decitabine + azacitidineEisaiApproved

✅DeferasiroxNovartisApproved

✅ICL670/DeferasiroxNovartisApproved

✅deferasiroxNovartisApproved

✅DeferasiroxNovartisApproved

✅Epoetin betaRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00111462	Phase 2	Completed	—	—	Anemia
NCT00036023	Phase 2	Completed	—	—	Lymphoma
NCT01428154	Phase 1	Withdrawn	Apr 1, 2016	Nov 1, 2016	Anemia
NCT02175277	Phase 3	Completed	Jun 12, 2014	Mar 20, 2017	Myelodysplastic Syndrome (MDS)
NCT01652872	Phase 3	Completed	Jul 30, 2012	Oct 19, 2017	Anemia in Chronic Kidney Disease Patients Not on Dialysis
NCT00925587	Phase 3	Completed	Jun 1, 2009	May 1, 2012	Anemia
NCT00883415	Pre-clinical	Completed	May 1, 2008	Nov 1, 2012	Cardiomyopathy
NCT00381836	Phase 2/3	Terminated	Oct 1, 2006	Feb 1, 2007	Prostatic Neoplasms
NCT00355407	Pre-clinical	Completed	Jun 1, 2006	Aug 1, 2007	Hematologic Malignancies
NCT00436995	Phase 3	Completed	Apr 1, 2006	Dec 1, 2008	Chronic Kidney Disease
NCT00239239	Phase 2	Completed	Aug 1, 2005	Mar 1, 2007	Non-Myeloid Malignancies
NCT00121602	Phase 3	Completed	Mar 1, 2005	Oct 1, 2006	Anemia
NCT00135317	Phase 3	Completed	Nov 1, 2004	—	Cancer
NCT00095277	Phase 2	Completed	Oct 1, 2004	—	Anemia
NCT00096915	Phase 3	Completed	Oct 1, 2004	Nov 1, 2005	Kidney Disease
NCT00095264	Phase 2	Completed	Oct 1, 2004	—	Myelodysplastic Syndromes
NCT00111098	Phase 3	Completed	Mar 1, 2004	Nov 1, 2005	Kidney Disease
NCT00144755	Phase 3	Completed	Dec 1, 2003	Dec 1, 2012	Diffuse Large Cell Lymphoma
NCT00153868	Approved	Completed	Oct 1, 2003	Aug 17, 2007	Anemia
NCT00086086	Phase 2	Completed	Aug 1, 2003	—	Congestive Heart Failure

Competing Products

20 competing products in Myelodysplastic Syndrome (MDS)

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	23
JSP191	Jasper Therapeutics	Phase 1	11
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	35
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	35
Decitabine + Valproic Acid	Eisai	Phase 2	35
decitabine + decitabine	Eisai	Phase 2	35
decitabine + azacitidine	Eisai	Approved	35
Decitabine	Eisai	Phase 2	27
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	29
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	35
Subcutaneous Decitabine	Eisai	Phase 1	21
Decitabine	Eisai	Phase 2	35
Galunisertib + Placebo	Eli Lilly	Phase 2/3	38
DSP-7888	Sumitomo Pharma	Phase 1/2	32
TP-0184	Sumitomo Pharma	Phase 1/2	24
Decitabine	Johnson & Johnson	Phase 2	35
Epoetin alfa	Johnson & Johnson	Phase 2	27
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	35